MDxHealth has filed a patent for a method of diagnosing prostate cancer using expression level analysis of molecular markers. The method involves determining the expression levels of DLX1 and HOXC6 in a sample and comparing them to reference values to establish the presence or absence of prostate cancer. If cancer is detected, treatment can be administered. The method can be used with readily obtainable samples such as urine or prostatic fluid. GlobalData’s report on MDxHealth gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on MDxHealth, personalized medicine biomarkers was a key innovation area identified from patents. MDxHealth's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Method for diagnosing prostate cancer using expression markers
A recently filed patent (Publication Number: US20230151427A1) describes a method for in vitro establishing prostate cancer (PrCa) in a sample from a human individual suspected of or suffering from prostate cancer. The method involves determining the expression levels of specific genes, DLX1 and HOXC6, and establishing their up-regulation compared to individuals without prostate cancer or a reference value. Based on this up-regulation, the presence or absence of prostate cancer can be established, and if cancer is present, treatment can be administered.
The patent also includes variations of the method, such as determining the expression level of additional genes, HOXC4 and TDRD1, and using their up-regulation along with DLX1 and HOXC6 to establish the presence or absence of prostate cancer. The method can be applied to various sample types, including urine, urine-derived, prostatic fluid, prostatic fluid-derived, ejaculate, and ejaculate-derived samples.
The patent further describes the use of mRNA expression levels to determine the expression levels of the genes. Specifically, the method can be used in individuals with a serum prostate-specific antigen (sPSA) level of 4-10 ng/ml. The treatment for prostate cancer can include various options such as surgery, radiation therapy, radiopharmaceutical therapy, hormone therapy, chemotherapy, biologic therapy, bisphosphonate therapy, cryotherapy, high-intensity focused ultrasound therapy, proton beam radiation therapy, or a combination thereof.
In addition to the method itself, the patent also includes a system for obtaining RNA from a urine sample and detecting mRNA of the genes DLX1 and HOXC6. The system can also include components for detecting mRNA of the genes HOXC4 or TDRD1. Furthermore, the system can include components for obtaining a urine sample and a therapeutic agent for treating prostate cancer.
Lastly, the patent describes a kit of parts for in vitro establishing prostate cancer in a sample. The kit includes expression level analysis means for determining the expression levels of HOXC6 and DLX1, and optionally, the expression level of HOXC4 and TDRD1.
Overall, this patent presents a method, system, and kit for accurately establishing the presence or absence of prostate cancer based on the expression levels of specific genes in a sample, allowing for targeted treatment decisions.